Skip to main content
Top

2009 | OriginalPaper | Hoofdstuk

23 Ziekte van Huntington

Auteur : H.P.H. Kremer

Gepubliceerd in: Handboek dementie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Kernpunten

  • De ziekte van Huntington is een autosomaal dominante erfelijke hersenaandoening met zogenaamde complete penetrantie.
  • De aandoening wordt veroorzaakt door een geëxpandeerde trinucleotide repeat (CAG-repeat) in het huntingtine-gen op de korte arm van chromosoom 4.
  • De klinische verschijnselen zijn te rangschikken als stemmings- en gedragsproblemen, motorische (extrapiramidale) problemen en cognitieve achteruitgang.
  • De diagnose kan met 100% zekerheid worden vastgesteld of worden uitgesloten met behulp van DNA-Diagnostiek.
  • Er bestaat geen behandeling die de progressieve neurodegeneratie kan stoppen; wel zijn er medicamenteuze behandelmogelijkheden voor symptomen zoals stemmingsstoornissen, gedragsproblemen en onwillekeurige bewegingen.
Literatuur
go back to reference Barbeau A, Duvoisin RC, Gerstenbrand F, Lakke JP, Marsden CD, Stern G. Classification of extrapyramidal disorders. Proposal for an international classification and glossary of terms. J Neurol Sci. 1981;51(2):311-27. Barbeau A, Duvoisin RC, Gerstenbrand F, Lakke JP, Marsden CD, Stern G. Classification of extrapyramidal disorders. Proposal for an international classification and glossary of terms. J Neurol Sci. 1981;51(2):311-27.
go back to reference Beglinger LJ, Langbehn DR, Duff K, Stierman L, Black DW, Nehl C et al. Probability of obsessive and compulsive symptoms in Huntington’s disease. Biol Psychiatry. 2007;61(3):415-8. Beglinger LJ, Langbehn DR, Duff K, Stierman L, Black DW, Nehl C et al. Probability of obsessive and compulsive symptoms in Huntington’s disease. Biol Psychiatry. 2007;61(3):415-8.
go back to reference Bonelli RM, Wenning GK. Pharmacological management of Huntington’s disease: an evidence-based review. Curr Pharm Des. 2006;12(21):2701-20. Bonelli RM, Wenning GK. Pharmacological management of Huntington’s disease: an evidence-based review. Curr Pharm Des. 2006;12(21):2701-20.
go back to reference Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(4):219-26. Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(4):219-26.
go back to reference Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington’s chorea. Curr Med Res Opin. 1984;9(5):329-38. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington’s chorea. Curr Med Res Opin. 1984;9(5):329-38.
go back to reference Ehret JC, Day PS, Wiegand R, Wojcieszek J, Chambers RA. Huntington disease as a dual diagnosis disorder: data from the National Research Roster for Huntington disease patients and families. Drug Alcohol Depend. 2007;86(2-3):283-6. Ehret JC, Day PS, Wiegand R, Wojcieszek J, Chambers RA. Huntington disease as a dual diagnosis disorder: data from the National Research Roster for Huntington disease patients and families. Drug Alcohol Depend. 2007;86(2-3):283-6.
go back to reference Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986;24(2): 305-11. Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986;24(2): 305-11.
go back to reference Folstein SE, Folstein MF. Psychiatric features of Huntington’s disease: recent approaches and findings. Psychiatr Dev. 1983;1(2):193-205. Folstein SE, Folstein MF. Psychiatric features of Huntington’s disease: recent approaches and findings. Psychiatr Dev. 1983;1(2):193-205.
go back to reference Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57(3):397-404. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57(3):397-404.
go back to reference Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330(20):1401-6. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med. 1994;330(20):1401-6.
go back to reference Landwehrmeyer GB, Dubois B, de Yebenes JG, Kremer B, Gaus W, Kraus PH et al. Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62(3):262-72. Landwehrmeyer GB, Dubois B, de Yebenes JG, Kremer B, Gaus W, Kraus PH et al. Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62(3):262-72.
go back to reference Naarding P, Kremer HP, Zitman FG. Huntington’s disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry. 2001;16(8):439-45. Naarding P, Kremer HP, Zitman FG. Huntington’s disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry. 2001;16(8):439-45.
go back to reference Schoenfeld M, Myers RH, Cupples LA, Berkman B, Sax DS, Clark E. Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1984;47(12):1283-7. Schoenfeld M, Myers RH, Cupples LA, Berkman B, Sax DS, Clark E. Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1984;47(12):1283-7.
go back to reference Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366-72. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366-72.
go back to reference The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971-83. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971-83.
go back to reference Wiggins S, Green T, Adam S, Hayden MR. A long term (ca 5 years) prospective assessment of psychological consequences of predictive testing for Huntington disease (HD). Am J Hum Genet. 1996; 59(4):A7. Wiggins S, Green T, Adam S, Hayden MR. A long term (ca 5 years) prospective assessment of psychological consequences of predictive testing for Huntington disease (HD). Am J Hum Genet. 1996; 59(4):A7.
go back to reference Wild EJ, Tabrizi SJ. Huntington’s disease phenocopy syndromes. Curr Opin Neurol. 2007;20(6):681-7. Wild EJ, Tabrizi SJ. Huntington’s disease phenocopy syndromes. Curr Opin Neurol. 2007;20(6):681-7.
Metagegevens
Titel
23 Ziekte van Huntington
Auteur
H.P.H. Kremer
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8061-9_23